Key result
Hetastarch for post-SAH vasospasm is linked to ~38% longer PTT and frequent bleeding compared to PPF.
Observational (n=26)
Answers are grounded in this paper and cite their sources.
The use of colloid agents to achieve hypervolemia in the prevention and treatment of postsubarachnoid hemorrhage (post-SAH) vasospasm is included in the standard of care at many institutions. Risk profiles are necessary to ensure appropriate use of these agents. In a series of 85 patients with recent aneurysmal SAH, 26 developed clinical symptoms of vasospasm. Fourteen of the 26 were treated with hetastarch for volume expansion while the other 12 received plasma protein fraction (PPF). Clinically significant bleeding pathologies were noted in six patients who received hetastarch as a continuous intravenous infusion. Hetastarch increased partial thromboplastin time from a mean of 23.9 seconds to a mean of 33.1 seconds (p < 0.001) in all patients who received infusions of this agent, while no effect was noted in the 12 patients who received PPF infusions. No other coagulation parameters were altered. This study shows an increase in coagulopathy with the use of hetastarch as compared with the use of PPF for the treatment of postaneurysmal vasospasm.
No takes yet. Share an insight, caveat, or question.
Trumble et al. (1995) conducted an observational in Postsubarachnoid hemorrhage (post-SAH) vasospasm (n=26). Hetastarch continuous intravenous infusion vs. Plasma protein fraction (PPF) infusion was evaluated on Partial thromboplastin time (PTT) and clinically significant bleeding pathologies (p=< 0.001). Hetastarch infusion for post-SAH vasospasm increased mean partial thromboplastin time from 23.9s to 33.1s and caused bleeding in 6/14 patients, unlike PPF.
Synapse has enriched 10 related papers. Consider them for comparative context: